Last reviewed · How we verify
NCT05875909
Corneal Flap Transplantation for Macular Hole Repair of High Myopia
NA trial testing corneal flap transplantation in Retinal Perforations in 30 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | First People's Hospital of Hangzhou |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 February 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- corneal flap transplantation
Conditions studied
- Retinal Perforations — all drugs for Retinal Perforations →
- Myopia, Degenerative — all drugs for Myopia, Degenerative →
Sponsor
First People's Hospital of Hangzhou
Who can join
Adults 18 to 80, any sex, with Retinal Perforations or Myopia, Degenerative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn about an innovative surgical technique for macular hole repair. This technique is for patients with high myopia using pars plana vitrectomy (PPV) combined with corneal flap transplantation. The main questions it aims to answer are: * Is the innovative surgical technique useful for patients? * Is the surgical technique safe for patients? Participants will: * Undergo PPV combined with corneal flap transplantation to cover the macular hole. * Maintain a prone position for 2 weeks postoperatively. * Be observed by visual acuity, slit lamp, optical coherence tomography (OCT) and fundus photography for 1 year after surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Corneal stromal lenticule transplantation for covering macular hole during vitrectomy.
Ding WT, Xu YL, Li D, Qian XX, et al · · 2025 · PMID 40534794 · DOI 10.18240/ijo.2025.06.24
Verify or expand the search:
- PubMed search for NCT05875909
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other First People's Hospital of Hangzhou trials
Trials by the same sponsor.
- NCT07507825 — Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) · Phase 2 · not yet recruiting
- NCT07390981 — Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder · NA · not yet recruiting
- NCT07242443 — Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Py · Phase 4 · not yet recruiting
- NCT07207278 — Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma · recruiting
- NCT06933992 — Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05875909 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First People's Hospital of Hangzhou
- Last refreshed: 25 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05875909.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing